Topas Therapeutics will be translational partner for CRC focused on liver inflammation

Topas Therapeutics, a German-based platform company, will serve as the exclusive translational partner for the recently extended Collaborative Research Center (CRC) 841, ‘Liver inflammation: infection, immune regulation and consequences’.

CRCs are funded by the German Research Foundation and CRC 841 has received funding since 2010. With this announcement, it has also been revealed that funding for CRC 841 will be extended for four years, which should equate to around €15 million.

“From the very beginning, the translation of research into potential clinical applications has been a focus of CRC 841, and we now expect a nanomedicine for the treatment of autoimmune diseases originally developed at CRC 841 to enter human clinical testing in 2019,” explained Professor Ansgar W. Lohse, chief of the I. Medical Clinic and Polyclinic for Internal Medicine at the UKE and CRC spokesperson. “The collaboration with Topas has been a great success and we look forward to continuing to work together.”

Topas plans to translate the eight years of research of CRC 841 into clinical development. In addition, Topas will cooperate closely with various members of the CRC to explore additional applications of Topas' immune tolerance approach in various indications and to integrate these into Topas' project portfolio, where appropriate.